Tech Company Financing Transactions
OncoTartis Funding Round
Private investors, Norma Investments and Pharmstandard participated in a $6 million funding round for OncoTartis. The funding round was announced on 12/12/2017.
Transaction Overview
Company Name
Announced On
12/12/2017
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
640 Ellicott St. 480
Buffalo, NY 14203
USA
Buffalo, NY 14203
USA
Phone
Website
Email Address
Overview
OncoTartis, Inc. is a private biotechnology company established in 2011. The company's founding IP came from Prof. Andrei Gudkov's laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexander Polinsky
Chief Scientific Officer
Andrei Gudkov
VP - Operations
Aleksandra Kotlyarova
VP - R & D
Olga Chernova
Browse more venture capital transactions:
Prev: 12/12/2017: Ouster venture capital transaction
Next: 12/12/2017: Fuzzy Pet Health venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs